Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/21/2024 | $45.00 | Buy | Citigroup |
| 10/21/2024 | $42.00 | Buy | Jefferies |
| 10/21/2024 | $40.00 | Overweight | Morgan Stanley |
Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesity Completed $238.3 million initial public offering and concurrent private placement, cash and cash equivalents sufficient to fund operations and capital expenditures into 2029 Appointed former GSK CEO Jean-Pierre Garnier as Board Chair RICHMOND, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging, today provided business updates and reported its third quarter 2024 financial results. "The third quarter of 20
STOCKHOLM, Nov. 6, 2024 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ:BIOA) (STOCKHOLM: BIOA B) has presented the design of its proprietary BrainTransporter (BT) platform at the 16th annual Protein & Antibody Engineering Summit (PEGS) conference in Barcelona, Spain. The BT platform uses active Transferrin Receptor (TfR)-mediated transport, enabling up to 70-fold higher penetration of antibodies over the blood brain barrier, without negative effects on hematological safety parameters. During the 16th annual Protein & Antibody Engineering Summit (PEGS) Europe conference, Dr. Per-Ola Freskgård, VP Science & Technology at BioArctic, presented for the first time the design of the proprietary BT pl
RICHMOND, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging, today announced that it will present new preclinical data for its lead product candidate azelaprag, an orally available small molecule agonist of the apelin receptor APJ. The data will be presented at ObesityWeek 2024, held in San Antonio from November 2–6, 2024. "Our preclinical data highlight the potential of azelaprag as a novel oral therapy for obesity," said Kristen Fortney, Ph.D., CEO and co-founder of BioAge. "Our two presentations provide e
SC 13D - BioAge Labs, Inc. (0001709941) (Subject)
SC 13D - BioAge Labs, Inc. (0001709941) (Subject)
4 - BioAge Labs, Inc. (0001709941) (Issuer)
4 - BioAge Labs, Inc. (0001709941) (Issuer)
4 - BioAge Labs, Inc. (0001709941) (Issuer)
Citigroup initiated coverage of BioAge Labs with a rating of Buy and set a new price target of $45.00
Jefferies initiated coverage of BioAge Labs with a rating of Buy and set a new price target of $42.00
Morgan Stanley initiated coverage of BioAge Labs with a rating of Overweight and set a new price target of $40.00
10-Q - BioAge Labs, Inc. (0001709941) (Filer)
8-K - BioAge Labs, Inc. (0001709941) (Filer)
8-K - BioAge Labs, Inc. (0001709941) (Filer)
4 - BioAge Labs, Inc. (0001709941) (Issuer)
4 - BioAge Labs, Inc. (0001709941) (Issuer)
4 - BioAge Labs, Inc. (0001709941) (Issuer)